Company Website

Contact information

Chris Aanerud
chris_aanerud@pharmaessentia.com
(612) 708-0677

Robin Fallon
robin_fallon@pharmaessentia.com
(402) 980-0634

Virtual Exhibit Hall Home

Redefining the treatment of hematologic diseases...
PharmaEssentia is working to redefine the potential of proven therapies to enhance the health and quality of life for patients living with hematologic diseases. Powered by world-class expertise and grounded in pioneering science, we are developing novel treatment solutions, beginning with therapies for myeloproliferative neoplasms (MPNs).

Developing new early treatment options...
Patients with myeloproliferative neoplasms (MPNs) have limited treatment options today. A group of rare, chronic blood cancers, MPNs gradually impact patients’ quality of life and can lead to life-threatening forms of cancer. Existing treatments for some MPNs, such as polycythemia vera (PV) and essential thrombocythemia (ET), are focused on managing the symptoms and reducing the risk of complications. PharmaEssentia is working diligently to provide physicians and patients with options that aim to reduce the risk of disease progression.

Additional Information:

SOURCE Access & Support Application- BESREMi (ropefinterferon alfa-2b)
NCCN Guidelines for BESREMi (ropeginterferon alfa-2b)  
BESREMi (ropeginterferon alfa-2b) Packet Insert US  
BESREMi (ropeginterferon alfa-2b) Dosing & Titration